BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26870808)

  • 1. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS
    EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
    BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
    Singer CF; Muhr D; Rappaport C; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Pfeiler G; Berger A; Sun P; Narod SA
    Clin Genet; 2014 Jan; 85(1):72-5. PubMed ID: 23772696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
    Appel SJ; Cleiment RJ
    J Natl Black Nurses Assoc; 2015 Dec; 26(2):17-26. PubMed ID: 27045154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
    Walsh EM; Farrell MP; Nolan C; Gallagher F; Clarke R; McCaffrey JA; Kennedy MJ; Barry M; Kell MR; Gallagher DJ
    Ir J Med Sci; 2016 Feb; 185(1):189-94. PubMed ID: 25673166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.
    Konstantopoulou I; Tsitlaidou M; Fostira F; Pertesi M; Stavropoulou AV; Triantafyllidou O; Tsotra E; Tsiftsoglou AP; Tsionou C; Droufakou S; Dimitrakakis C; Fountzilas G; Yannoukakos D
    Clin Genet; 2014 Jan; 85(1):36-42. PubMed ID: 24010542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers.
    Laitman Y; Vaisman Y; Feldman D; Helpman L; Gitly M; Paluch Shimon S; Berger R; Cohen L; Narod SA; Friedman E
    Clin Genet; 2014 Jan; 85(1):68-71. PubMed ID: 23517234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
    Randall TC; Armstrong K
    Curr Treat Options Oncol; 2016 Aug; 17(8):39. PubMed ID: 27315065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
    Bick U; Engel C; Krug B; Heindel W; Fallenberg EM; Rhiem K; Maintz D; Golatta M; Speiser D; Rjosk-Dendorfer D; Lämmer-Skarke I; Dietzel F; Schäfer KWF; Leinert E; Weigel S; Sauer S; Pertschy S; Hofmockel T; Hagert-Winkler A; Kast K; Quante A; Meindl A; Kiechle M; Loeffler M; Schmutzler RK;
    Breast Cancer Res Treat; 2019 May; 175(1):217-228. PubMed ID: 30725383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
    Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; ; Hopper JL; Phillips KA
    Med J Aust; 2013 Nov; 199(10):680-3. PubMed ID: 24237098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model for estimating ovarian cancer risk: application for preventive oophorectomy.
    Giannakeas V; Sopik V; Shestopaloff K; Iqbal J; Rosen B; Akbari M; Narod SA
    Gynecol Oncol; 2015 Nov; 139(2):242-7. PubMed ID: 26341709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.
    Arai M; Yokoyama S; Watanabe C; Yoshida R; Kita M; Okawa M; Sakurai A; Sekine M; Yotsumoto J; Nomura H; Akama Y; Inuzuka M; Nomizu T; Enomoto T; Nakamura S
    J Hum Genet; 2018 Apr; 63(4):447-457. PubMed ID: 29176636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammographic density and breast cancer in women from high risk families.
    Ramón Y Cajal T; Chirivella I; Miranda J; Teule A; Izquierdo Á; Balmaña J; Sánchez-Heras AB; Llort G; Fisas D; Lope V; Hernández-Agudo E; Juan-Fita MJ; Tena I; Robles L; Guillén-Ponce C; Pérez-Segura P; Luque-Molina MS; Hernando-Polo S; Salinas M; Brunet J; Salas-Trejo MD; Barnadas A; Pollán M
    Breast Cancer Res; 2015 Jul; 17(1):93. PubMed ID: 26163143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
    Menkiszak J; Chudecka-Głaz A; Gronwald J; Bedner R; Cymbaluk-Płoska A; Wezowska M; Zielińska D; Rzepka-Górska I
    Ginekol Pol; 2013 Sep; 84(9):758-64. PubMed ID: 24191513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
    Fostira F; Tsitlaidou M; Papadimitriou C; Pertesi M; Timotheadou E; Stavropoulou AV; Glentis S; Bournakis E; Bobos M; Pectasides D; Papakostas P; Pentheroudakis G; Gogas H; Skarlos P; Samantas E; Bafaloukos D; Kosmidis PA; Koutras A; Yannoukakos D; Konstantopoulou I; Fountzilas G
    Breast Cancer Res Treat; 2012 Jul; 134(1):353-62. PubMed ID: 22434525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.